Oligonucleotide & Peptide Therapeutic Development & Commercialization
Oligonucleotide and peptide therapeutics offer promising treatments for a wide range of medical conditions.
Specifically, they provide the opportunity to develop therapeutics that affect protein targets that cannot be effectively treated by small-molecule or protein therapeutics. BioTechLogic’s team of experts has deep expertise and experience working on the front lines of oligonucleotide and peptide therapeutic development, from preclinical to market.
Complete Oligonucleotide & Peptide Therapeutic Lifecycle Support Services
BioTechLogic has extensive experience with oligonucleotide- and peptide-based therapeutic development and commercialization. We have extensive experience working with advanced analytical methods that better characterize and quantitate both the oligonucleotide and peptides of interest, as well as any synthesis contaminants.
Oligonucleotide & Peptide Therapeutic Development & Production
BioTechLogic has done a great deal of work with oligonucleotide and peptide products, including process validation work for drug substance, drug product, and oligo adjuvant.
How BioTechLogic Can Help
-
- Product characterization
- Analytical method development
- Critical Quality Attributes understanding
-
- CDMO selection support
- On-site batch run support
- Process control strategies
- Microbial monitoring strategies
-
- Commercialization plans
- Formulation development reports
- Chromatography column troubleshooting
- Regulatory filing support
Oligonucleotide & Peptide Therapeutics CMC Services
CMC Strategy
Quality Assurance
Analytical Services
Regulatory Consulting & Submissions Support
Process Development & Validation
Contract Services & Tech Transfer Support
Supply Chain Management
Inspection Readiness
Project Management
Years
Consultants
Clients
projects
Oligonucleotide & Peptide Therapeutic Resources
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
